Search Results
Jul 16, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jul 09, 2026, 17:40 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jun 25, 2026, 19:36 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jun 18, 2026, 21:41 ET Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)
professionals. Hundreds of millions recovered.Frequently Asked Questions About the NVCR Investigation Q: Who is eligible to participate in the NVCR investigation? A: Investors who purchased NVCR stock or securities and suffered financial losses may be eligible. Eligibility is based
More news about: SueWallSt.com
Feb 25, 2026, 09:00 ET Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
(NASDAQ: ONCY), ImmunityBio (NASDAQ: IBRX), CRISPR Therapeutics (NASDAQ: CRSP), BioNTech (NASDAQ: BNTX), and Novocure (NASDAQ: NVCR).
More news about: Equity Insider
Feb 17, 2026, 11:25 ET New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
data in tumor types that have resisted conventional approaches for decades. Oncolytics Biotech Inc. (NASDAQ: ONCY), Novocure (NASDAQ: NVCR), Perspective Therapeutics, Inc. (NYSE-A: CATX), ImmunityBio, Inc. (NASDAQ: IBRX), and Nuvation Bio Inc. (NYSE: NUVB) each represent
More news about: Equity Insider
Feb 17, 2026, 11:17 ET New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
data in tumor types that have resisted conventional approaches for decades. Oncolytics Biotech Inc. (NASDAQ: ONCY), Novocure (NASDAQ: NVCR), Perspective Therapeutics, Inc. (NYSE-A: CATX), ImmunityBio, Inc. (NASDAQ: IBRX), and Nuvation Bio Inc. (NYSE: NUVB) each represent
More news about: Equity Insider